Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -8 of 8
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/29/2008
 
First Published:
12/8/2006
1.
Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV, Phase III
Treatment
Active
21 and under
Other
GPOH-NB2004
EU-20661, NCT00410631
2.
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
MIP-IB12
NCT00458952
Last Modified:
7/17/2007
 
First Published:
3/24/2005
3.
Phase II Pilot Study of Targeted Radiotherapy Using Iodine I 131 Metaiodobenzylguanidine Combined With Arsenic Trioxide in Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Chromaffin Cell Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 1
Other
MSKCC-04148
NCT00107289
Last Modified:
10/2/2007
 
First Published:
11/4/2005
4.
Phase II Study of Iodine I 131 Metaiodobenzylguanidine and Combination Chemotherapy Comprising Carboplatin, Etoposide, and Melphalan Followed By Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation and Radiotherapy in Patients With Relapsed or Refractory Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
1 to 29
NCI
NANT-2001-02
NCT00253435
Last Modified:
9/15/2008
 
First Published:
4/15/2008
5.
Phase II Study of Iodine I 131 Metaiodobenzylguanidine and Autologous Stem Cell Transplantation in Young Patients With Relapsed or Refractory High-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
1 to 30
NCI, Pharmaceutical / Industry
NANT-2007-01
NANT2007-01, NANT-MIP-IB13, NCT00659984, MIPI-NANT-2007-01
Last Modified:
10/2/2007
 
First Published:
7/24/2007
6.
Phase I Study of Irinotecan Hydrochloride, Vincristine, and Iodine I 131 Metaiodobenzylguanidine in Young Patients With Resistant or Relapsed High-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
1 to 30
NCI
NANT-2004-06
NANT 2004-06, NANT-N04-06, NANT-Draximage-2007-01, NCT00509353
7.
Diagnosis of Pheochromocytoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Biomarker/Laboratory analysis, Diagnostic
Active
Not specified
NICHD
000093
00-CH-0093, NCT00004847
Last Modified:
10/2/2007
 
First Published:
8/30/2007
8.
Randomized Study of Standard Induction Chemotherapy Versus Topotecan Hydrochloride-Containing Induction Chemotherapy Followed by Myeloablative Autologous Stem Cell Transplantation and Consolidation Therapy With Isotretinoin in Pediatric Patients With High-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Active
6 months to 21
Other
GPOH-NB2004-HR
NB2004-HR, UNI-KOELN-161, NCT00526318
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute